News
8h
ZME Science on MSNA Common Cough Syrup Might Protect the Brain in Parkinson’s DementiaThe drug is Ambroxol. It’s been used for decades to treat respiratory ailments by thinning mucus and easing coughs. But now, ...
A decades-old cough medicine, Ambroxol, could be on the verge of a dramatic second act—not for sore throats, but for ...
23h
ScienceAlert on MSNCough Medicine May Protect Against Some of Parkinson's Worst SymptomsAn active ingredient in cough medicines since 1979 has shown promise as a treatment for neuropsychiatric symptoms in ...
Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over 12 months, whereas placebo patients worsened. Those with high-risk ...
Today’s cough syrup could turn into tomorrow’s treatment for Parkinson’s disease. Recent research in the U.K. is the latest to suggest that a common ingredient in cough syrup, ambroxol, might be able ...
Ambroxol supports a key enzyme called glucocerebrosidase (GCase), which is produced by the GBA1 gene. In people with Parkinson's disease, GCase levels are often low.
Researchers at Lawson Research Institute are studying Ambroxol - a common cough medicine in Europe - as a potential treatment for dementia linked to Parkinson’s disease LONDON, Ont. – Dementia ...
A COMMON cough medicine could help protect against dementia. A study found that it prevented people with Parkinson’s develop the memory-destroying disease. Around 145,000 people in the UK hav… ...
Ambroxol, a common cough medicine used in Europe, demonstrated target engagement in people with Parkinson's disease dementia but did not show an effect on cognition compared with placebo, a year ...
Now, a new year-long clinical trial suggests that the cough medicine Ambroxol – used safely for decades in Europe – can potentially slow the development of these symptoms.
Ambroxol supports a key enzyme called glucocerebrosidase (GCase), which is produced by the GBA1 gene. In people with Parkinson's disease, GCase levels are often low.
Ambroxol was safe, well-tolerated and reached therapeutic levels in the brain. Psychiatric symptoms worsened in the placebo group but remained stable in those taking Ambroxol.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results